Cerebral Infarction Drugs Market Players:
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sanofi-aventis Groupe
- Abbott Laboratories
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Amneal Pharmaceuticals, Inc.
- Novartis AG
- Pfizer Inc.
- Edwards Lifesciences Corporation
- Daiichi Sankyo Company, Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of cerebral infarction drugs is estimated at USD 9.28 billion.
The global cerebral infarction drugs market size crossed USD 8.64 billion in 2025 and is likely to register a CAGR of over 8.2%, exceeding USD 19 billion revenue by 2035.
North America is poised to hold a 50% share by 2035, driven by the rising prevalence of cerebrovascular disease, sedentary lifestyles, and increasing approvals for novel drug delivery systems.
Key players in the market include Amgen Inc., Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Edwards Lifesciences Corporation, Daiichi Sankyo Company, Limited.
